Drugs / CD34+ bone marrow stem cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01736059 | Jul 2012 → Oct 2026 expected | diabetic retinopathy, dry age related macular degeneration, hereditary macular dystrophy, retinal vein occlusion +1 | University of California, Davis | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD34+ bone marrow stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01736059 ↗ |
| Modality | Cell therapy | “human bone marrow (BM) CD34+ stem cells” PMID 25491299 ↗ Dec 2014 |